Professor David Price
Chair of Primary Care Respiratory Med
- About
-
- Email Address
- d.price@abdn.ac.uk
- Telephone Number
- +44 (0)1224 437237
- School/Department
- School of Medicine, Medical Sciences and Nutrition
- Publications
-
Page 5 of 34 Results 101 to 125 of 832
Characterization of patients in the International Severe Asthma Registry with high steroid exposure who did or did not initiate biologic therapy
Journal of Asthma and Allergy, vol. 15, no. 15, pp. 1491—1510Contributions to Journals: ArticlesClinical outcomes in patients with severe asthma who had or had not initiated biologic therapy: results from the CLEAR study
CHEST 2022, pp. A28-A32Contributions to Journals: AbstractsClinical Review: The suggested management pathway for urticaria in primary care
Clinical and Translational Allergy, vol. 12, no. 10, e12195Contributions to Journals: ArticlesClinical outcomes and emergency healthcare utilization in patients with severe asthma who continued, switched or stopped biologic therapy: results from the CLEAR study
CHEST Annual Meeting, pp. A23-A27Contributions to Journals: AbstractsShort-acting β2-agonist prescription patterns for asthma management in the SABINA III primary care cohort
npj Primary Care Respiratory Medicine, vol. 32, 37Contributions to Journals: ArticlesSuboptimal peak inspiratory flow and critical inhalation errors are associated with higher COPD-related healthcare costs
International journal of chronic obstructive pulmonary disease , vol. 2022, no. 17, pp. 2401-2415Contributions to Journals: ArticlesOral corticosteroids in asthma and beyond: moving forward
European Respiratory Journal, vol. 60, no. 3, 2200776Contributions to Journals: EditorialsPatients with Chronic Obstructive Pulmonary Disease and Evidence of Eosinophilic Inflammation Experience Exacerbations Despite Receiving Maximal Inhaled Maintenance Therapy
International journal of chronic obstructive pulmonary disease , vol. 2022, no. 17, pp. 2187—2200Contributions to Journals: ArticlesPersistent Reductions in OCS Use in Patients With Severe, OCS-Dependent Asthma Treated With Dupilumab: LIBERTY ASTHMA TRAVERSE Study
NexusContributions to Conferences: AbstractsOral corticosteroid (OCS) risk predictor for Type II Diabetes in asthma
European Respiratory Society (ERS) International Congress., 4420Contributions to Journals: AbstractsOver-the-counter (OTC) short-acting β2-agonist (SABA) purchase and asthma outcomes in SABINA III
European Respiratory Society (ERS) International Congress.Contributions to Journals: AbstractsPatient-reported barriers to accepting a technological adherence package in the MAGNIFY trial
European Respiratory Society (ERS) International Congress., 3402Contributions to Journals: AbstractsSociodemographic and clinical characteristics of patients with asthma who were prescribed ≥3 SABA canisters/year in the SABINA International study
European Respiratory Society (ERS) International Congress., 3397Contributions to Journals: AbstractsMortality Analyses on Systemic Corticosteroid Use: a Long-term Observational Study
BTS Winter Meeting 2021, pp. A7-A8Contributions to Journals: Abstracts- [ONLINE] DOI: https://doi.org/10.1136/thorax-2021-BTSabstracts.11
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstream/2164/23330/1/Xu_etal_BTS2021_Mortality_Analyses_On_AAM.pdf
- [ONLINE] https://www.brit-thoracic.org.uk/document-library/winter-meetings/winter-meeting-2021/winter-meeting-2021-abstract-programme/
Persistent Reductions in OCS Use in Patients With Severe, OCS-Dependent Asthma Treated With Dupilumab: LIBERTY ASTHMA TRAVERSE Study
Eastern Pulmonary Conference 2022Contributions to Conferences: AbstractsA pragmatic primary practice approach to using specific IgE in allergy testing in asthma diagnosis, management, and referral
Journal of Asthma and Allergy, vol. 2022, no. 15, pp. 1069—1080Contributions to Journals: ArticlesPersistent reductions in OCS use in patients with severe, OCS dependent asthma treated with dupilumab: LIBERTY ASTHMA TRAVERSE study
World Allergy Congress 2022Contributions to Conferences: AbstractsCorrespondence to Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA2LEN consensus
Allergy, vol. 77, no. 8, pp. 2571-2573Contributions to Journals: Letters- [ONLINE] DOI: https://doi.org/10.1111/all.15281
- [ONLINE] View publication in Scopus
Dupilumab Treatment Leads to Sustained Reductions in Oral Corticosteroid Use in Patients With Oral Corticosteroid–Dependent Severe Asthma
CHEST 2022Contributions to Conferences: AbstractsCOPD Population in US Primary Care: Data From the Optimum Patient Care DARTNet Research Database and the Advancing the Patient Experience in COPD Registry
Annals of Family Medicine, vol. 20, no. 4, pp. 319-327Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1370/afm.2829
Oral corticosteroid (OCS) risk predictor for Type II Diabetes in asthma
European Respiratory Society (ERS) International Congress.Contributions to Conferences: AbstractsA Response to: Letter to the Editor Regarding “Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab”
Advances in Therapy, vol. 39, no. 8, pp. 3862-3865Contributions to Journals: LettersPersistent Reductions in OCS Use in Patients With Severe, OCS-Dependent Asthma Treated With Dupilumab: LIBERTY ASTHMA TRAVERSE Study
17th Annual Deutscher Allergiekongress (DAK) 2022Contributions to Conferences: AbstractsCharacterisation of the Australian adult population living with asthma: Severe exacerbation frequency, long-term OCS use and adverse effects.
Pragmatic and Observational Research, vol. 2022, pp. 43-58Contributions to Journals: ArticlesHealthcare resource utilisation associated with intermittent oral corticosteroid use in asthma
EAACI HYBRID CONGRESS 2022Contributions to Conferences: Abstracts